Skadden, Arps, Slate, Meagher & Flom and Zhong Lun Law Firm have advised China’s Everest Medicines on its $451 million IPO in Hong Kong, with Kirkland & Ellis and Tian Yuan Law Firm advising the joint sponsors and underwriters.

Everest Medicines, a China-based clinical-stage biopharmaceutical company created by C-Bridge Capital in July 2017, develops, licenses and commercialises potentially novel transformative therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets.

It is the second Chinese biopharmaceutical company to go public in Hong Kong this month, after JHBP (CY) Holdings.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

SAM, Luthra, Simmons guide planned $360 mln India renewable energy IPO

by Asian Legal Business《亚洲法律杂志》 |

Shardul Amarchand Mangaldas & Co is advising Indian renewable energy firm ACME Solar Holdings on its planned 30-billion-rupee ($360 million) initial public offering, with Luthra & Luthra Law Offices and Simmons & Simmons representing the book-running lead managers.

Deals

Paul Hastings advises Korean gaming firm on $315 mln IPO

by Asian Legal Business《亚洲法律杂志》 |

U.S. law firm Paul Hastings has advised Tencent-backed South Korean gaming company Shift Up on its 435-billion-won ($315 million) initial public offering on the Korea Exchange.

Deals

Latham, Links advise on Malaysia's largest IPO in 2 years

by Asian Legal Business《亚洲法律杂志》 |

Latham & Watkins and Mah-Kamariyah & Philip Koh have advised Malaysian palm oil company Johor Plantations Group on its 735-million-ringgit ($157 million) initial public offering, the country's biggest in more than two years.